Dr. Wu Zhuang 庄武
Chief Physician
Department of Thoracic Medical Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer, esophageal cancer, malignant pleural effusion, and pericardial effusion.
Dr. Zhuang is Administrative Director and Chief Physician of the Department of Thoracic Medical Oncology at Fujian Cancer Hospital. Research focuses on basic and clinical thoracic oncology and molecular pathology testing. Dr. Zhuang has published over 30 papers, including 5 SCI-indexed articles, and presented at conferences such as ASCO, ESMO, and WCLC. Dr. Zhuang leads or participates in six provincial-level research projects.
Professional roles
- Standing Committee Member and Secretary, Lung Cancer Professional Committee, Fujian Anti-Cancer Association
- Standing Committee Member, China Precision Medicine Professional Committee
- Member, Lung Cancer Prevention and Control Branch, China International Exchange and Promotion Association for Medical and Healthcare
- Member, Esophageal Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Zhuang Wu). Papers usually list the name as Wu Zhuang or Zhuang W.
Selected publications
77 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- 3 Biotech, 2026 (senior author): EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism. PubMed 42781045
- Environ Toxicol, 2024 (senior author): High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11. PubMed 38642004
- Cancer Biother Radiopharm, 2020 (senior author): Mortal Obligate RNA Transcript Inhibits Cancer Cell Invasion and Migration in Lung Adenocarcinoma by Downregulating miRNA-223. PubMed 32160014
- Chin Med J (Engl), 2019 (senior author): Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma. PubMed 31809319
- J Cancer, 2018 (first author): The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. PubMed 30026825
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion